Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment
- PMID: 20063406
- DOI: 10.1002/mds.22928
Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment
Abstract
Alpha-synuclein (alpha-syn) is an intracellular protein with a high tendency to aggregation. It is the major component of Lewy bodies and may play a key role in the pathogenesis of Parkinson's disease (PD). alpha-Syn is also released by neurons and can be detected in biological fluids, such as plasma. The purpose of this study was to determine whether plasma alpha-syn concentrations are elevated in newly diagnosed PD patients before treatment (nontreated PD group, ntPD; n = 53) and to compare them with concentrations in PD patients with at least 1 year of specific treatment (tPD; n = 42) and in healthy controls (n = 60). Plasma alpha-syn concentrations in the ntPD and tPD groups were similar and significantly higher than in healthy controls. In conclusion, alpha-syn was elevated early in the development of PD and specific PD treatment did not change plasma alpha-syn levels.
Similar articles
-
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.FASEB J. 2006 Mar;20(3):419-25. doi: 10.1096/fj.03-1449com. FASEB J. 2006. PMID: 16507759
-
Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.FASEB J. 2011 Dec;25(12):4127-37. doi: 10.1096/fj.10-179192. Epub 2011 Aug 24. FASEB J. 2011. PMID: 21865317
-
Plasma alpha-synuclein is decreased in subjects with Parkinson's disease.Exp Neurol. 2007 Apr;204(2):583-8. doi: 10.1016/j.expneurol.2006.12.006. Epub 2006 Dec 19. Exp Neurol. 2007. PMID: 17258710
-
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.Biomark Med. 2010 Oct;4(5):683-99. doi: 10.2217/bmm.10.90. Biomark Med. 2010. PMID: 20945981 Review.
-
Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.Exp Brain Res. 2006 Aug;173(2):223-33. doi: 10.1007/s00221-006-0539-y. Epub 2006 May 30. Exp Brain Res. 2006. PMID: 16733698 Review.
Cited by
-
Αlpha-synuclein levels in blood plasma from LRRK2 mutation carriers.PLoS One. 2012;7(12):e52312. doi: 10.1371/journal.pone.0052312. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300640 Free PMC article.
-
Blood biomarker-based classification study for neurodegenerative diseases.Sci Rep. 2023 Oct 11;13(1):17191. doi: 10.1038/s41598-023-43956-4. Sci Rep. 2023. PMID: 37821485 Free PMC article.
-
Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.J Neural Transm (Vienna). 2017 Mar;124(3):353-360. doi: 10.1007/s00702-016-1650-2. Epub 2016 Nov 22. J Neural Transm (Vienna). 2017. PMID: 27878377
-
Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.Sci Rep. 2023 Mar 30;13(1):5217. doi: 10.1038/s41598-023-32480-0. Sci Rep. 2023. PMID: 36997567 Free PMC article.
-
A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Mov Disord. 2017. PMID: 28734051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous